Urinary excretion and metabolism of the α-pyrrolidinophenone designer drug 1-phenyl-2-(pyrrolidin-1-yl)octan-1-one (PV9) in humans

Forensic Toxicology

Volumn 33, Issue 2, 2015, Pages 279-294

  Shima, Noriaki ^a   Kakehashi, Hidenao ^a   Matsuta, Shuntaro ^a   Kamata, Hiroe ^a   Nakano, Shihoko ^a   Sasaki, Keiko ^a   Kamata, Tooru ^a   Nishioka, Hiroshi ^a   Zaitsu, Kei ^b   Sato, Takako ^c   Miki, Akihiro ^a   Katagi, Munehiro ^a   Tsuchihashi, Hitoshi ^c  

^a Chuo ward   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Cathinone derivative; LC MS MS; Metabolism; PV9; Urine; POP

Indexed keywords

1 PHENYL 2 (2 OXOPYRROLIDIN 1 YL)OCTAN 1 ONE; 1 PHENYL 2 (PYRROLIDIN 1 YL)OCTAN 1 OL; 1 PHENYL 2 (PYRROLIDIN 1 YL)OCTAN 1 ONE; 1 PHENYL 2 (PYRROLIDIN 1 YL)OCTAN 1,7 DIOL; 1 PHENYL 2 (PYRROLIDIN 1 YL)OCTAN 1,7 DIONE; 7 HYDROXY 1 PHENYL 2 (PYRROLIDIN 1 YL)OCTAN 1 ONE; 8 HYDROXY 1 PHENYL 2 (PYRROLIDIN 1 YL)OCTAN 1 ONE; 8 HYDROXY 8 PHENYL 7 (PYRROLIDIN 1 YL)OCTANOIC ACID; 8 OXO 8 PHENYL 7 (PYRROLIDIN 1 YL)OCTANOIC ACID; ALPHA PYRROLIDINOPHENONE; CARBOXYLIC ACID; CATHINONE; KETONE; UNCLASSIFIED DRUG;

ALIPHATIC OXIDATION; ARTICLE; CHEMICAL STRUCTURE; CONJUGATION; DRUG CONTROL; ELECTROSPRAY MASS SPECTROMETRY; FORENSIC TOXICOLOGY; GAS CHROMATOGRAPHY; HYDROLYSIS; HYDROXYLATION; LIQUID CHROMATOGRAPHY; METABOLISM; OXIDATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; URINALYSIS; URINARY EXCRETION;

EID: 84937515487     PISSN: 18608965     EISSN: 18608973     Source Type: Journal    
DOI: 10.1007/s11419-015-0274-9     Document Type: Article

References (34)

1. Valente MJ, Guedes de Pinho P, de Lourdes Bastos M, Carvalho F, Carvalho M (2014) Khat and synthetic cathinones: a review. Arch Toxicol 88:15–45
2. Paillet-Loilier M, Cesbron A, Le Boisselier R, Bourgine J, Debruyne D (2014) Emerging drugs of abuse: current perspectives on substituted cathinones. Subst Abuse Rehabil 5:37–52
3. Cottencin O, Rolland B, Karila L (2014) New designer drugs (synthetic cannabinoids and synthetic cathinones): review of literature. Curr Pharm Des 20:4106–4111
4. Uchiyama N, Shimokawa Y, Kawamura M, Kikura-Hanajiri R, Hakamatsuka T (2014) Chemical analysis of a benzofuran derivative, 2-(2-ethylaminopropyl)benzofuran (2-EAPB), eight synthetic cannabinoids, five cathinone derivatives, and five other designer drugs newly detected in illegal products. Forensic Toxicol 32:266–281
5. Jane MP, Lewis SN (2012) The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol 8:33–42
6. Wyman JF, Lavins ES, Engelhart D, Armstrong EJ, Snell KD, Boggs PD, Taylor SM, Norris RN, Miller FP (2013) Postmortem tissue distribution of MDPV following lethal intoxication by “bath salts”. J Anal Toxicol 37:182–185
7. Meyer MR, Du P, Schuster F, Maurer HH (2010) Studies on the metabolism of the α-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC–MS and LC–high resolution MS and its detectability in urine by GC–MS. J Mass Spectrom 45:1426–1442
8. Shima N, Katagi M, Kamata H, Matsuta S, Sasaki K, Kamata T, Nishioka H, Miki A, Tatsuno M, Zaitsu K, Ishii A, Sato T, Tsuchihashi H, Suzuki K (2014) Metabolism of the newly encountered designer drug α-pyrrolidinovalerophenone in humans: identification and quantitation of urinary metabolites. Forensic Toxicol 32:59–67
9. Tyrkkö E, Pelander A, Ketola R, Ojanperä I (2013) In silico and in vitro metabolism studies support identification of designer drugs in human urine by liquid chromatography/quadrupole-time-of-flight mass spectrometry. Anal Bioanal Chem 405:6697–6709
10. Hasegawa K, Suzuki O, Wurita A, Minakata K, Yamagishi I, Nozawa H, Gonmori K, Watanabe K (2014) Postmortem distribution of α-pyrrolidinovalerophenone and its metabolite in body fluids and solid tissues in a fatal poisoning case measured by LC–MS-MS with the standard addition method. Forensic Toxicol 32:225–234
11. Sauer S, Peters FT, Haas C, Meyer MR, Fritschi G, Maurer HH (2009) New designer drug α-pyrrolidinovalerophenone (PVP): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J Mass Spectrom 44:952–964
12. Saito T, Namera A, Osawa M, Aoki H, Inokuchi S (2013) SPME–GC–MS analysis of α-pyrrolidinovalerophenone in blood in a fatal poisoning case. Forensic Toxicol 31:328–332
13. Namera A, Konuma K, Kawamura M, Saito T, Nakamoto A, Yahata M, Ohta S, Miyazaki S, Shiraishi H, Nagao M (2014) Time-course profile of urinary excretion of intravenously administered α-pyrrolidinovalerophenone and α-pyrrolidinobutiophenone in a human. Forensic Toxicol 32:68–74
14. Matsuta S, Shima N, Kamata H, Kakehashi H, Nakano S, Sasaki K, Kamata T, Nishioka H, Miki A, Katagi M, Zaitsu K, Sato T, Tsuchihashi H, Suzuki K (2015) Metabolism of the designer drug α-pyrrolidinobutiophenone (α-PBP) in humans: identification and quantification of the phase I metabolites in urine. Forensic Sci Int 249:181–188
15. Namera A, Urabe S, Saito T, Torikoshi-Hatano A, Shiraishi H, Arima Y, Nagao M (2013) A fatal case of 3,4-methylenedioxypyrovalerone poisoning: coexistence of α-pyrrolidinobutiophenone and α-pyrrolidinovalerophenone in blood and/or hair. Forensic Toxicol 31:338–343
16. Sauer C, Hoffmann K, Schimmel U, Peters FT (2011) Acute poisoning involving the pyrrolidinophenone-type designer drug 4′-methyl-alpha-pyrrolidinohexanophenone (MPHP). Forensic Sci Int 208:20–25
17. Westphal F, Junge T, Rösner P, Fritschi G, Klein B, Girreser U (2007) Mass spectral and NMR spectral data of two new designer drugs with an alpha-aminophenone structure: 4′-methyl-alpha-pyrrolidinohexanophenone and 4′-methyl-alpha-pyrrolidinobutyrophenone. Forensic Sci Int 169:32–42
18. Meyer MR, Mauer S, Meyer GM, Dinger J, Klein B, Westphal F, Maurer HH (2014) The in vivo and in vitro metabolism and the detectability in urine of 3′,4′-methylenedioxy-alpha-pyrrolidinobutyrophenone (MDPBP), a new pyrrolidinophenone-type designer drug, studied by GC–MS and LC–MS(n.). Drug Test Anal 6:746–756
19. Hasegawa K, Wurita A, Minakata K, Gonmori K, Nozawa H, Yamagishi I, Suzuki O, Watanabe K (2014) Identification and quantitation of a new cathinone designer drug PV9 in an “aroma liquid” product, antemortem whole blood and urine specimens, and a postmortem whole blood specimen in a fatal poisoning case. Forensic Toxicol 32:243–250
20. Hasegawa K, Wurita A, Minakata K, Gonmori K, Nozawa H, Yamagishi I, Watanabe K, Suzuki O (2015) Postmortem distribution of PV9, a new cathinone derivative, in human solid tissues in a fatal poisoning case. Forensic Toxicol 33:141–147
21. Iversen L, White M, Treble R (2014) Designer psychostimulants: pharmacology and differences. Neuropharmacology 87:59–65
22. Zaitsu K, Katagi M, Tsuchihashi H, Ishii A (2014) Recently abused synthetic cathinones, α-pyrrolidinophenone derivatives: a review of their pharmacology, acute toxicity, and metabolism. Forensic Toxicol 32:1–8
23. Marusich JA, Antonazzo KR, Wiley JL, Blough BE, Partilla JS, Baumann MH (2014) Pharmacology of novel synthetic stimulants structurally related to the “bath salts” constituent 3,4-methylenedioxypyrovalerone (MDPV). Neuropharmacology 87:206–213
24. Kaizaki A, Tanaka S, Numazawa S (2014) New recreational drug 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone (alpha-PVP) activates central nervous system via dopaminergic neuron. J Toxicol Sci 39:1–6
25. Simmler LD, Buser TA, Donzelli M, Schramm Y, Dieu LH, Huwyler J, Chaboz S, Hoener MC, Liechti ME (2013) Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 168:458–470
26. Baumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M, Rothman RB, Goldberg SR, Lupica CR, Sitte HH, Brandt SD, Tella SR, Cozzi NV, Schindler CW (2013) Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive ‘bath salts’ products. Neuropsychopharmacology 38:552–562
27. Strano-Rossi S, Cadwallader AB, de la Torre X, Botrè F (2010) Toxicological determination and in vitro metabolism of the designer drug methylenedioxypyrovalerone (MDPV) by gas chromatography/mass spectrometry and liquid chromatography/quadrupole time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 24:2706–2714
28. Springer D, Fritschi G, Maurer HH (2003) Metabolism of the new designer drug α-pyrrolidinopropiophenone (PPP) and the toxicological detection of PPP and 4-methyl-α-pyrrolidinopropiophenone (MPPP) studied in rat urine using gas chromatography mass spectrometry. J Chromatogr B 796:253–266
29. Shin H-S, Shin Y-SO, Lee S, Park B-B (1996) Detection and identification of pyrovalerone and its hydroxylated metabolite in the rat. J Anal Toxicol 20:568–572
30. Minakata K, Yamagishi I, Nozawa H, Hasegawa K, Wurita A, Gonmori K, Suzuki M, Watanabe K, Suzuki O (2015) Determination of new pyrrolidino cathinone derivatives, PVT, F-PVP, MPHP, PV8, PV9 and F-PV9, in human blood by MALDI-Q-TOF mass spectrometry. Forensic Toxicol 33:148–154
31. Shima N, Katagi M, Kamata H, Matsuta S, Nakanishi K, Zaitsu K, Kamata T, Nishioka H, Miki A, Tatsuno M, Sato T, Tsuchihashi H, Suzuki K (2013) Urinary excretion and metabolism of the newly encountered designer drug 3,4-dimethylmethcathinone in humans. Forensic Toxicol 31:101–112
32. Zaitsu K, Katagi M, Kamata HT, Kamata T, Shima N, Miki A, Tsuchihashi H, Mori Y (2009) Determination of the metabolites of the new designer drugs bk-MBDB and bk-MDEA in human urine. Forensic Sci Int 188:131–139
33. Kamata HT, Shima N, Zaitsu K, Kamata T, Miki A, Nishikawa M, Katagi M, Tsuchihashi H (2006) Metabolism of the recently encountered designer drug, methylone, in humans and rats. Xenobiotica 36:709–723
34. Meyer MR, Wilhelm J, Peters FT, Maurer HH (2010) Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry. Anal Bioanal Chem 397:1225–1233